pedf-derived short peptide Updated Trends,PEDF and its functional peptide 44mer

Pigment epithelium-derived factor (PEDF), a naturally occurring glycoprotein with a molecular weight of approximately 50,000 daltons, has long been recognized for its potent anti-angiogenic properties. However, recent scientific endeavors have increasingly focused on PEDF-derived short peptides, revealing a diverse range of therapeutic applications stemming from fragments of this larger protein. These short peptides are demonstrating significant promise in areas ranging from ocular conditions and wound healing to neuroprotection and even cancer therapy.

One of the most compelling areas of research involves the therapeutic effects of PEDF-derived short peptides in treating eye diseases. Studies indicate that these peptides can be a promising agent for the treatment of Dry Eye Disease (DED). For instance, a specific PEDF 7-mer peptide has been shown to manifest anti-VEGF activity, a crucial factor in managing neovascularization associated with various ocular pathologies. Furthermore, research evaluating the efficacy of a pigment epithelium-derived factor (PEDF)-derived short peptide, specifically a 29-mer, on experimental dry eye in murine models has shown positive results, involving the suppression of MMP-9 and inflammation. This highlights the potential of PEDF-derived short peptides as ophthalmic drop treatments. The role of PEDF and its derived peptides in promoting survival and differentiation of photoreceptors and inducing neurite-outgrowth in amacrine cells further underscores their retinoprotective capabilities, with potential applications in Retinitis Pigmentosa (RP).

Beyond ocular health, PEDF-derived short peptides are proving valuable in regenerative medicine and wound healing. Investigations into pigment epithelium-derived factor short peptides have demonstrated their ability to facilitate full-thickness cutaneous wound healing by promoting epithelial basal cell and hair follicle regeneration. In fact, specific short peptides, such as 20- and 29-amino-acid variants, have significantly reduced the time required for wound healing in experimental models compared to control groups. Conversely, the loss of PEDF causes a distinctive wound healing phenotype characterized by increased angiogenesis and delayed resolution, emphasizing the importance of its derived peptides in this process. The application of PEDF-derived short peptides in tendon healing is also being explored, with pharmaceutical compositions containing these peptides being investigated for treating tendon injuries.

The underlying molecular mechanisms by which these PEDF-derived short peptides exert their effects are also being elucidated. One proposed mechanism involves PEDF receptor signalling linking to the SLC7A11/GSH/GPX4 axis to alleviate intracellular redox imbalance, suggesting a role in antioxidant defense. Research has identified a small peptide, H105A, from pigment epithelium-derived factor (PEDF) that can slow down degeneration, indicating a neuroprotective function. Studies have also shown that PEDF and its functional peptide 44mer protect cultured cells and primary cardiomyocytes against apoptosis and necroptosis under hypoxic conditions. Another significant finding is the anti-angiogenic activity of a PEDF-derived shorter peptide (PDSP), which has shown a regulatory role in healing corneal wounds in vivo models.

The potential of PEDF-derived short peptides extends to oncology, where their anti-angiogenic properties are being leveraged. Short pigment epithelial-derived factor-derived peptides have been investigated for their ability to inhibit angiogenesis and tumor growth. While PEDF itself is a potent angiogenesis inhibitor, some of its other functions can paradoxically enhance tumor growth, making its targeted peptide fragments a more precise therapeutic option.

Further research is exploring various PEDF peptides, including specific fragments like the P78-PEDF peptide, for their therapeutic potential in conditions such as diabetic renal injury. The development of compositions comprising pedf-derived short peptides for treating neurotrophic keratitis diseases also signifies a targeted therapeutic approach.

In summary, the PEDF-derived short peptide represents a versatile therapeutic agent with a broad spectrum of applications. From treating eye conditions and accelerating wound healing to offering neuroprotection and combating angiogenesis in cancer, these derived short peptide fragments of Pigment epithelial-derived factor (PEDF) are at the forefront of innovative biomedical research, offering new hope for various disease management strategies. The ongoing exploration of these pedf-derived short peptides promises to unlock even more of their potential in the future.